COMP <GO>
BCRX vs UNH // OPTIONS IMPLIED MOVE & PUT/CALL SKEW
BioCryst Pharmaceuticals Inc. (NASDAQ) VS. UnitedHealth Group Incorporated (NYSE) • 15-METRIC TALLY: BCRX 4
— UNH 4
■ METRIC PARITY
LAST: $8.52 (+1.79%) • MKT CAP: $2.18B
options-implied-move
—
LAST: $410.91 (+0.94%) • MKT CAP: $368.83B
options-implied-move
6.74%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (BCRX VS. UNH)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | BCRX | UNH | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | 88.57% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 85.00% | 11.47% | +73.53 | BCRX | /roic <GO> |
| EV/EBITDA & P/E Valuation | 6.1x | 16.4x | -10.35 | BCRX | /valuation <GO> |
| Free Cash Flow Yield | 15.96% | 6.48% | +9.48 | BCRX | /fcf-yield <GO> |
| Operating Margin | — | 4.82% | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | 3.14% | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | — | 6.46% | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.28% | -2.28 | UNH | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | 3.12 | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 6/9 | 7/9 | -1.00 | UNH | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew ACTIVE | — | 6.74% | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 55.8 | 59.2 | -3.40 | UNH | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 0.33 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 7.7x | 17.7x | -10.04 | BCRX | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $2.18B | $368.83B | -$366.65B | UNH | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | BCRX REV | UNH REV | BCRX GROSS % | UNH GROSS % | BCRX FCF | UNH FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | $447.57B | — | 88.7% | $347.4M | $16.07B |
| FY 2024 | $0 | $400.28B | — | 88.3% | -$52.0M | $20.70B |
| FY 2023 | $0 | $371.62B | — | 89.6% | -$95.1M | $25.68B |
| FY 2022 | — | $324.16B | — | 89.6% | — | $23.40B |
| FY 2021 | — | $287.60B | — | 89.2% | — | $19.89B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
BCRX // BETA —
UNH // BETA 0.33